Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.79 and traded as low as $0.68. Karyopharm Therapeutics shares last traded at $0.70, with a volume of 998,124 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KPTI. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Piper Sandler upped their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Price Performance

The company has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.83. The stock has a market capitalization of $85.34 million, a P/E ratio of -0.59 and a beta of 0.05.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the firm posted ($0.30) earnings per share. As a group, equities research analysts predict that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors have recently modified their holdings of KPTI. Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics during the second quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new stake in Karyopharm Therapeutics during the 2nd quarter valued at $167,000. Exchange Traded Concepts LLC boosted its position in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the period. Finally, FMR LLC grew its stake in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).